In the December 3, 2014 issue of JAMA, the guidelines for cervical cancer screening developed by the American College of Obstetricians and Gynecologists (ACOG) were published. Highlights of the recommendations: Cervical cancer screening should begin at age 21, with no prior screening regardless of sexual activity or risk group. For women aged 21-29 years, cervical cytology (TCT) should be performed every three years. For women aged 30-65 years, cervical cytology (TCT) with combined human papillomavirus (HPV) screening every five years, or cytology every three years as an alternative screening method. Women at high risk for cervical cancer should be screened more frequently (HIV infection, immunocompromise, uterine exposure to hexestrol, or presence of cervical intraepithelial neoplasia [CIN]2, CIN3, or carcinoma). Screening may be discontinued in women older than 65 years of age if negative screening results are evident and there are no CIN grade 2 or higher lesions (3 consecutive negative cytology results or 2 consecutive negative combined results in the last 5 years of the previous 10 years). Cervical cells can be collected by liquid or conventional cervical smear. HPV tests alone are not acceptable as screening results. If the results of the combined test show cytologic findings of atypical squamous cells of uncertain significance (ASCUS) and negative HPV, routine screening will continue according to age. If the results of the combined test show negative cytologic results and positive HPV results, the combined test should be repeated within 12 months or a special HPV genotype test should be performed. Screening recommendations are consistent regardless of whether a woman has received the HPV vaccine.